Immune checkpoint inhibitors (ICIs) have improved the prognosis for patients with metastatic melanoma but exposed them to immune-related adverse events (irAEs). Cutaneous toxic effects are one of the most prevalent irAEs, particularly maculopapular rash, pruritus, and vitiligo, but others have been reported, such as sclerodermoid reaction.1 The management of these irAEs is challenging. We report a case of corticosteroid-refractory ICI-induced generalized morphea that was successfully treated with tocilizumab, an anti–interleukin-6 (IL-6) receptor monoclonal antibody.